We also described how mutated BRAF affected tumor angiogenesis and proved that targeting BRAFV600E stabilized the tumor vascular bed and abrogated hypoxia in mouse xenografts (Bottos et al., 2012). The gene discussed is BRAF; the disease is neoplasm.